The subject of gene patentability is one of the most controversial topics in life sciences. In June 2013, the US Supreme Court reached a unanimous decision in the Association for Molecular Pathology v Myriad Genetics. It stated that companies cannot patent parts of naturally occurring human genes. Managing IP sat down with Fitzpatrick Cella Harper & Scinto attorneys Robert Fischer, John Carlin and Joshua Rothman to discuss the ruling
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
A new transatlantic firm under the name of Winston Taylor is expected to go live in May 2026, and is likely to have a significant impact on Europe’s IP market
Geoff Steward and Rebecca Newman of Addleshaw Goddard explain how they secured victory in a rare ‘genericide’ case and why the work went beyond the courtroom
Price hikes at ‘big law’ firms are pushing some clients toward boutiques that offer predictable fees, specialised expertise, and a model built around prioritising IP
The Australian side, in particular, can benefit by capitalising on its independent status to bring in more work from Western countries while still working with its former Chinese partner